Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	134 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean change from baseline in Simpson-Angus Scale score –0.21 with clozapine (250–600 mg/day) –0.6 with ziprasidone (80–160 mg/day)	Reported as not significant		Not significant
RCT	139 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean change from baseline in Barnes Akathisia Scale score –0.37 with clozapine (250–600 mg/day) –0.22 with ziprasidone (80–160 mg/day)	Reported as not significant		Not significant
RCT	139 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean change from baseline in Abnormal Involuntary Movement Scale (AIMS) score –0.15 with clozapine (250–600 mg/day) –0.08 with ziprasidone (80–160 mg/day)	Reported as not significant		Not significant
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean difference in change from baseline in weight (kg) 0.8 kg with clozapine (250–600 mg/day) 2.6 kg with ziprasidone (80–160 mg/day)	P <0.001	Effect size not calculated	clozapine
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Change from baseline in median prolactin (ng/mL) –5.0 ng/mL with clozapine (250–600 mg/day) –6.5 ng/mL with ziprasidone (80–160 mg/day)	Significance assessment not performed
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean change from baseline in heart rate (bpm) 2.0 bpm with clozapine (250–600 mg/day) 8.0 bpm with ziprasidone (80–160 mg/day)	Reported as not significant		Not significant
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean change from baseline in QTc (ms) +6.0 ms with clozapine (250–600 mg/day) –3.6 ms with ziprasidone (80–160 mg/day)	Reported as not significant		Not significant
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Mean change from baseline in total cholesterol –5.0 with clozapine (250–600 mg/day) +2.0 with ziprasidone (80–160 mg/day)	P <0.05	Effect size not calculated	ziprasidone
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Incidence of increased salivation 0% with clozapine (250–600 mg/day) 29% with ziprasidone (80–160 mg/day) Absolute numbers not reported	Significance assessment not performed
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Incidence of tachycardia 3% with clozapine (250–600 mg/day) 29% with ziprasidone (80–160 mg/day) Absolute numbers not reported	Significance assessment not performed
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Incidence of somnolence 4% with clozapine (250–600 mg/day) 23% with ziprasidone (80–160 mg/day) Absolute numbers not reported	Significance assessment not performed
RCT	146 people with resistance and/or intolerance to at least 3 acute cycles of different antipsychotics in the past 5 years	Incidence of insomnia 10% with clozapine (250–600 mg/day) 3% with ziprasidone (80–160 mg/day) Absolute numbers not reported	Significance assessment not performed